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Background: Immune regulation is among the noncalcemic effects of vitamin D. So, this
vitamin may play a role in autoimmune diseases such as systemic lupus erythematosus
(SLE).
Objectives: To study the prevalence of vitamin D deﬁciency in SLE and its association with
clinical, serological and treatment proﬁle as well as with disease activity.
Methods: Serum OH vitamin D3 levels were measured in 153 SLE patients and 85 controls.
Data on clinical, serological and treatment proﬁle of lupus patients were obtained through
chart review. Blood cell count and SLEDAI (SLE disease activity index) were measured simul-
taneously with vitamin D determination.
Results: SLE patients have lower levels of vitamin D than controls (p = 0.03). In univariate
analysis serum vitamin D was associated with leukopenia (p = 0.02), use of cyclophos-
phamide (p = 0.007) and methotrexate (p = 0.03). A negative correlation was veriﬁed with
prednisone dose (p = 0.003). No association was found with disease activity measured by
SLEDAI (p = 0.88). In a multiple regression study only leukopenia remained as an independent
association (B = 4.04; p = 0.02). A negative correlation of serum vitamin level with granulocyte
(p  = 0.01) was also found, but not with lymphocyte count (p = 0.33).
Conclusion: SLE patients have more deﬁciency of vitamin D than controls. This deﬁciency is
not  associated with disease activity but with leucopenia (granulocytopenia).
© 2015 Elsevier Editora Ltda. All rights reserved.
Acerca  de  lúpus,  vitamina  D  e  leucopenia
Palavras-chave:
Lúpus eritematoso sistêmico
r  e  s  u  m  o
Introduc¸ão: A regulac¸ão imune está entre os efeitos não calcêmicos da vitamina D. Assim,
essa vitamina pode inﬂuenciar em doenc¸as autoimunes, como o lúpus eritematoso
Vitamina D sistêmico (LES).
revalência da deﬁciência de vitamina D no LES e sua associac¸ão comLeucopenia Objetivos: Estudar a p
Granulocitopenia o  perﬁl clínico, sorológico e de tratamento, bem como com a atividade da doenc¸a.
Métodos: Mensuraram-se os níveis séricos de OH-vitamina D3 em 153 pacientes com LES e
85  controles. Os dados sobre o perﬁl clínico, sorológico e de tratamento de pacientes com
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lúpus foram obtidos por meio da revisão de prontuários. Simultaneamente à determinac¸ão
da  vitamina D, foi feito um hemograma e foi aplicado o Sledai (SLE disease activity índex
[índice de atividade da doenc¸a no LES]).
Resultados: Os pacientes com LES tinham níveis mais baixos de vitamina D do que os con-
troles (p = 0,03). Na análise univariada, a vitamina D sérica esteve associada à leucopenia
(p  = 0,02) e ao uso de ciclofosfamida (p = 0,007) e metotrexato (p = 0,03). Foi veriﬁcada uma
correlac¸ão  negativa com a dose de prednisona (p = 0,003). Não foi encontrada associac¸ão com
a  atividade da doenc¸a medida pelo Sledai (p = 0,88). Em um estudo de regressão múltipla,
somente a leucopenia permaneceu como uma associac¸ão independente (B = 4,04; p = 0,02).
Também foi encontrada correlac¸ão negativa do nível sérico de vitamina D com os granulóc-
itos (p = 0,01), mas não com a contagem de linfócitos (p = 0,33).
Conclusão: Os pacientes com LES têm mais deﬁciência de vitamina D do que os controles.
Essa  deﬁciência não está associada com a atividade da doenc¸a, mas com a leucopenia
(granulocitopenia).
©  2015 Elsevier Editora Ltda. Todos os direitos reservados.
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itamin D has immune modulatory properties.1 The main
ource of vitamin for humans is the conversion of 7-
ehydrocholesterol in pre vitamin D3 in the skin, which
ccurs by exposure to ultraviolet radiation.2 A small portion
omes from the diet, mainly seafood 17. Vitamin D3 must
rst undergo one hydroxylation in the liver resulting in 25 OH
itamin D3 or calcidiol2 which is the circulating form of the
itamin and that it was the form used for serum measure-
ent at present. The most active form of vitamin D is 1,25
OH)2 vitamin D synthesized in the kidney.2 It is known that
his vitamin plays an inhibitory role of dendritic cells, CD4,
D8, B lymphocytes and the production of cytokines, such as
FN , IL-2, IL-6, TNF-, and increases the number of T regula-
ory cells and synthesis of other cytokines such as IL-4, IL-10
nd TGF .1,3,4 Thus it is conceivable that serum vitamin D
evels exert inﬂuence on autoimmune diseases such as SLE.
owever existing studies in this area are contradictory. Bir-
ingham et al.5 reported that patients with acute disease ﬂare
ave lower levels of vitamin D but a cause-effect relationship
ould not be established. Others noted that deﬁciency of vita-
in  D has been associated with increased disease activity,6–8
hile others denied it.4,9,10 Some clinical manifestations have
een associated with vitamin D levels such as leukopenia4
enal involvement,4 photosensitivity and the presence of anti-
s DNA.7
The vitamin D receptor gene polymorphism has been
inked with SLE susceptibility in Asian, Polish and Egyp-
ian patients.11–13 In Brazilians this association could not be
emonstrated although it seemed to inﬂuence the appearance
f cutaneous and articular manifestations and in the presence
f anti-ds DNA.14
Some factors contribute to a higher prevalence of vitamin
 deﬁciency in SLE patients than in the general population.
he photoprotection, held as part of the disease treatment,
an block the synthesis of cholecalciferol induced by UVB
adiation on the skin.15 Antimalarials, widely used in this dis-
ase, are described by some authors to be associated with its
eﬁciency due to its photoprotective effect.16 Others believethat this medication hinders the production of dihydrox-
yvitamin D as they inhibit the alpha-hydroxylase enzyme
responsible for transformation of mono in dihydroxyvitamin
D.17 This action could increase circulating levels of the level
of monohidroxy vitamin D3 in detriment of dyhidroxy active
form.17
In the present study we  aimed to determine whether the
levels of vitamin D in a Southern Brazilian population with SLE
are associated with disease activity, serological, clinical proﬁle
and with medications used for treatment.
Methods
This study was approved by the local Ethics Committee in
Research and all participants signed an informed consent.
One hundred and ﬁfty three patients with at least 4 of 1997
modiﬁed American College of Rheumatology (ACR) classiﬁ-
cation criteria for SLE18 were invited to participate during
the period of six months, according to the order of consul-
tation in the clinic and willingness to participate in the study.
We excluded patients using anticonvulsants with creatinine
greater than 1.3 mg/dL and pregnant women. None of the
included patients had made replacement of vitamin D in the
last year and none made use of more  than 600 IU of vita-
min  D3/day, which is routinely done in the service for all
glucocorticoids users. Demographic, clinical and serological
data were collected through chart review. Clinical data were
considered a cumulative way and deﬁned according to the
1997 ACR classiﬁcation criteria for SLE.18 Disease activity was
calculated by SLEDAI (or SLE Disease activity index).19 Also,
data on creatinine levels and blood cell count were collected
simultaneously with vitamin D as well as the drugs consid-
ered for study were those used at the moment of vitamin D
determination.
As controls, we  included 85 self-reported healthy individ-
uals from the same geographical area, matched for age and
gender.The serum vitamin D (25 OH vitamin D3)  was analyzed by
chemiluminescence by the Liaisom 25OH Vitamin D Assay
(DiaSorin Inc., Stillwater, MN, USA). Value ≥30 mg/dL were
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Table 1 – Clinical, serological and treatment proﬁle of
153 patients with systemic lupus erythematous.
n
Arthritis 86/140 61.4%
Serositis 34/105 32.3%
Hemolytic anemia 12/139 8.6%
Leukopenia 40/139 28.7%
Thrombocytopenia 35/136 25.7%
Glomerulonephrites 60/140 42.8%
Discoid lesions 15/136 11.0%
Malar rash 72/134 53.7%
Photossensitivity 103/148 69.5%
Oral ulcers 55/138 39.8%
Seizures 17/137 12.4%
Psychosis 9/96 9.3%
Anti Ro 53/137 38.6%
Anti La 25/136 18.3%
Anti Sm 37/132 28.0%
Anti ds DNA 48/136 35.9%
Anti cardiolipin IgG 18/136 13.2%
Anti cardiolipin IgM 17/136 12.5%
Lupus anticoagulante 14/118 11.7%
Azathioprine use 29/145 20%
Methotrexate use 22/145 15.5%
Mophetyl mycophenolate
use
17/145 11.7%
Cyclophosphamide use 11/145 7.5%
Antimalarial use 124/153 81.0%
Prednisone use 84/153 37.9%
Dosage 5–60 mg/day;
median = 10 (IQR = 5.0–27.5)
Creatinine level (mg/dL) 0.5–1.3 (0.77 ± 0.18)
Hematocrit (%) 23.8–52.8 (39.8 ± 4.27)
Platellet Platelet (/mm3) 570,000–534,000
(236,600 ± 74,641)
Total leukocyte (/mm3) 1720–17,800 (6431 ± 2907)
Lymphocyte (/mm3) 401–4913 (1719 ± 874)
Granulocyte (/mm3) 688–14,418 (4712 ± 2365)
The study of vitamin D levels and leukocyte cell count showed
no correlation of lymphocyte count with serum vitamin D
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considered normal; between 20 and 29 mg/dL were consid-
ered as vitamin insufﬁciency and values below 20 mg/dL as
deﬁciency.
Data were collected on the frequency and contin-
gency tables. Study of data distribution was performed by
the Kolmogorov–Smirnov test and central tendency was
expressed as median and interquartile range (IQR) for non-
parametric and mean and standard deviation for parametric
data. Association studies of vitamin D levels with clinical,
serological and demographic variables were made by Fisher’s
and chi-square when data was nominal and for unpaired t
test when nominal. Correlation studies of SLEDAI values, age,
prednisone dose, granulocyte and lymphocyte blood count
with values of serum vitamin D were done using Pearson and
Spearman test. All variables with p < 0.1 in univariate ana-
lyze were further studied through multiple linear regression
to access its independency. Calculations were made with help
of software Medcalc version 12.1.3.0 and the signiﬁcance was
set at 5%.
Results
Description  of  the  studied  sample
In the sample of 153 patients with SLE, 11/153 (7.1%) were men
and 142/153 (92.8%) were women aged 19–65 years (median 42
years, IQR = 31–49) and disease duration from 6 to 244 months
(median 36 months; IQR = 12–72). The SLEDAI values ranged
from 0 to 20 (median 0, IQR = 0–2). About 43/126 (34.1%) were
smokers. Patients’ clinical, serological and treatment proﬁle is
seen in Table 1.
In this sample the levels of serum vitamin D ranged from
4.0 to 57.2 (mean 22.5 ± 9.2). In 29/153 (18.9%) patients the val-
ues were normal; in 59/153 (38.5%) were insufﬁcient and 65/153
(42.4%) were deﬁcient. In 125/153 (81.6%) had values below the
normal range.
The 85 included controls had mean age 41.8 ± 16.4 years;
9/85 were men  and 76/85 women and they were matched for
age (p = 0.49) and gender (p = 0.36) with patients. The compar-
ison between the levels of vitamine D between SLE patients
and controls can be seen in Fig. 1.
Vitamin  D  in  SLE  population  according  to  demographic,
clinical,  serological  and  treatment  variables
The values of serum vitamin D levels according to studied
variables are seen in Table 2.
The correlation of vitamin D levels with prednisone dose
showed a negative value with rho = −0.23 (95% CI = −0.38 to
−0.07; p = 0.003) and a trend was observed with patients age
with rho = 0:07 (95% CI = −0.08 to 0.23, p = 0.360). No correlation
between vitamin D levels and SLEDAI was found (rho = −0.01,
95% CI = 0.15 to −0.17; p = 0.88).When variables with p < 0.1 in univariate analysis were
studied by multiple linear regression (prednisone, cyclophos-
phamide, methotrexate, leukopenia, anti Sm and Lupus
anticoagulant) only leukopenia remained as an independent
variable (B = 4.04; p = 0.02).IQR, interquartile range.
Study  of  leukopenia  with  serum  levels  of  vitamin  DPatients Controls
Fig. 1 – Vitamin D levels in systemic lupus erythematosus
patients (mean value 22.4 ± 9.16 mg/dLand controls (mean
value 25.6 ± 10.2 mg/dL) with p = 0.03.
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Table 2 – Comparison of vitamin D serum levels according to clinical demographic, serological and treatment variables.
Serum vitamin D (mg/dL)
mean ± SD (range) (with
the studied variable)
Serum vitamin D (mg/dL)
mean ± SD (range)
(without the studied
variable)
p
Gender (female) 22.59 ± 9.27 (4.1–57.2) 20.15 ± 7.10 (4.0–30.10) 0.39
Tobbaco use 22.30 ± 8.28 (4.1–45.1) 22.46 ± 9.52 (4.0–57.2) 0.92
Artrite 23.4 ± 9.7 (4.1–57.2) 21.8 ± 8.5 (4.0–47.0) 0.32
Serositis 20.8 ± 7.3(9.5–36.4) 23.04 ± 9.5 (4.0–57.2) 0.21
Hemolytic anemia 22.57 ± 8.9 (4.8–42.2) 22.51 ± 8.9 (4.0–57.2) 0.98
Leukopenia 21.4 ± 8.2 (4.0–45.1) 25.2 ± 10.3 (4.1–57.2) 0.02
Thrombocytopenia 22.03 ± 9.197 (4.1–45.1) 22.6 ± 9.2 (4.0–57.2) 0.73
Glomerulonephritis 21.95 ± 9.48 (4.0–48.0) 22.77 ± 9.12 (4.1–57.2) 0.60
Discoid lesions 22.55 ± 7.62 (4.1–33.0) 22.49 ± 9.40 (4.0–57.2) 0.98
Malar rash 21.70 ± 7.92 (8.0–47.0) 23.21 ± 10.23 (4.0–57.2) 0.31
Photossensitivity 22.16 ± 8.69 (4.1–48.0) 23.2 ± 10.28 (4.0–57.2) 0.51
Oral ulcers 23.21 ± 9.25 (4.9–57.2) 22.10 ± 9.22 (4.0–48.0) 0.47
Seizures 21.37 ± 8.69 (11.1–43.7) 22.64 ± 9.30 (4.0–57.2) 0.59
Psychosis 21.92 ± 7.98 (9.5–37.0) 22.54 ± 9.31 (4.0–57.2) 0.84
Anti Ro 21.89 ± 8.39 (4.8–48.0) 23.65 ± 10.59 (4.0–57.2) 0.26
Anti La 24.62 ± 11.76 (4.0–57.2) 22.09 ± 8.63 (4.83–48.0) 0.21
Anti Sm 24.81 ± 11.1 (4.8–57.2) 21.76 ± 8.45 (4.0–48.0) 0.07
Anti dsDna 23.18 ± 8.32 (4.9–45.1) 22.19 ± 9.62 (4.0–57.2) 0.53
Anti RNP 22.13 ± 9.81 (8.0–57.2) 22.63 ± 9.04 (4.0–48.0) 0.77
Anticardiolipin IgG 21.92 ± 2.90 (4.1–57.2) 22.58 ± 8.78 (4.0–48.0) 0.48
Anticardiolipin IgM 19.8 ± 6.9 (4.8–37.0) 22.9 ± 9.32 (4.0–57.2) 0.18
Lupus anticoagulante 18.2 ± 8.24 (4.9–33.7) 23.15 ± 8.93 (4.1–57.2) 0.06
Antimalarial use 22.66  ± 9.38 (4.0–57.2) 21.78 ± 8.54 (4.9–48.0 0.64
Azathioprine use 20.05 ± 8.81 (4.8–37.0) 23.07 ± 9.25 (4.0–57.2) 0.11
Methotrexate use 26.53 ± 8.08 (12.1–47.0) 21.87 ± 9.36 (4.0–57.2) 0.03
Mophetyl mycophenolate use 21.71 ± 9.70 (7.30–42.20) 22.50 ± 9.13 (4.0–57.2) 0.73
Cyclophosphamid use 15.28 ± 7.53 (4.0–33.0) 22.92 ± 9.07 (4.1–57.2) 0.007
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iscussion
he result of the present study conﬁrms the ﬁndings of other
uthors, showing that low levels of vitamin D are more  com-
on in lupus patients than in the normal population from
he same geographical area. This fact would be expected since
0 20 40 60 80
0
5000
10 000
15 000
20 000
D vitamin
G
ra
nu
lo
cy
te
s 
/m
m
3
ig. 2 – Correlation studies of serum vitamin d levels and
ranulocyte count (rho = −0.19;95% CI = −0.19 to −0.33;
 = 0.01).these patients are advised to avoid sunlight, the main source
of its synthesis. Autoantibodies against vitamin D have been
described in SLE, although they do not seem to affect the vita-
min  circulating levels.4 Also it was not possible to identify any
difference respecting antimalarial use ratifying the ﬁndings of
Fragoso et al.20 So the use of this medication cannot be implied
in the vitamin D deﬁciency.
At present, no correlation of vitamin D levels with disease
activity measured by SLEDAI was found but an interest-
ing association of vitamin D and leukopenia was conﬁrmed.
Bogaczewicz et al.4 have found that lower vitamin D level was
linked to leukopenia in 49 SLE patients. The same ﬁnding was
observed in 76 females with primary Sjögren syndrome by
Baldini et al.21 The importance of such ﬁnding is highlighted
when one notes that infections are a leading cause of death
in SLE patients.22 Bacterial infections are most frequent, fol-
lowed by viral and fungal infections.22
Vitamin D has a powerful effect in the differentia-
tion of cells of the myeloid lineage favoring monocyte
differentiation.23 Cultures of bone marrow cells in the pres-
ence of this vitamin result in a dramatic increase of monocytes
and macrophages from 12% in controls to 68% in treated
cultures.24 Furthermore, vitamin D suppresses neutrophil
differentiation.24 In a study of vitamin D-induced differ-
entiation in cultures of normal fetal liver blast cells, a
reciprocal promotion of maturation of cells from monocyte
lineage and a suppression of maturation of cells restricted
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to neutrophil development was observed. When treated
with (OH)2 vitamin D, these cultures produced 10 times
the number of monocytes than corresponding control cul-
tures. This was reﬂected by the control cultures holding ﬁve
times as many  neutrophils as the treated cultures.25 Ratify-
ing these studies we  found, at present, a negative association
of vitamin D levels with granulocyte peripheral count. Nev-
ertheless no association of this vitamin serum level could
be found with lymphocyte count. It is important to remem-
ber that lymphocyte counts in SLE patients may be altered
by others interfering factors such as the presence of lym-
phocytotoxic autoantibodies. These autoantibodies appear
in 36–90% of lupus patients and are associated with lower
count of leucocytes and with higher disease activity.26,27
Reduced surface expression of complement regulatory pro-
teins such as CD55 and CD59 has also been implicated
in the pathogenesis of lupus lymphopenia as this deﬁ-
ciency will turn the cells susceptible to complement-mediated
lysis.28
Summarizing, the present study shows that vitamin D
serum levels are lower in lupus patients than in controls. No
relationship of this vitamin serum level with disease activity
could be found but a negative relation with leucocytes number
was established. Further studies are needed in order to clarify
the importance of this vitamin deﬁciency in the prevalence of
infections in these patients.
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